John mascola
Cited by
Cited by
Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine
LR Baden, HM El Sahly, B Essink, K Kotloff, S Frey, R Novak, D Diemert, ...
New England journal of medicine 384 (5), 403-416, 2021
An mRNA vaccine against SARS-CoV-2—preliminary report
LA Jackson, EJ Anderson, NG Rouphael, PC Roberts, M Makhene, ...
New England journal of medicine 383 (20), 1920-1931, 2020
Antibody resistance of SARS-CoV-2 variants B. 1.351 and B. 1.1. 7
P Wang, MS Nair, L Liu, S Iketani, Y Luo, Y Guo, M Wang, J Yu, B Zhang, ...
Nature 593 (7857), 130-135, 2021
Rational design of envelope identifies broadly neutralizing human monoclonal antibodies to HIV-1
X Wu, ZY Yang, Y Li, CM Hogerkorp, WR Schief, MS Seaman, T Zhou, ...
Science 329 (5993), 856-861, 2010
Protection of macaques against vaginal transmission of a pathogenic HIV-1/SIV chimeric virus by passive infusion of neutralizing antibodies
JR Mascola, G Stiegler, TC VanCott, H Katinger, CB Carpenter, ...
Nature medicine 6 (2), 207-210, 2000
SARS-CoV-2 mRNA vaccine design enabled by prototype pathogen preparedness
KS Corbett, DK Edwards, SR Leist, OM Abiona, S Boyoglu-Barnum, ...
Nature 586 (7830), 567-571, 2020
Structural basis for broad and potent neutralization of HIV-1 by antibody VRC01
T Zhou, I Georgiev, X Wu, ZY Yang, K Dai, A Finzi, Y Do Kwon, JF Scheid, ...
Science 329 (5993), 811-817, 2010
Human Immunodeficiency Virus Type 1 env Clones from Acute and Early Subtype B Infections for Standardized Assessments of Vaccine-Elicited Neutralizing …
M Li, F Gao, JR Mascola, L Stamatatos, VR Polonis, M Koutsoukos, ...
Journal of virology 79 (16), 10108-10125, 2005
Evaluation of the mRNA-1273 vaccine against SARS-CoV-2 in nonhuman primates
KS Corbett, B Flynn, KE Foulds, JR Francica, S Boyoglu-Barnum, ...
New England Journal of Medicine 383 (16), 1544-1555, 2020
Co-evolution of a broadly neutralizing HIV-1 antibody and founder virus
HX Liao, R Lynch, T Zhou, F Gao, SM Alam, SD Boyd, AZ Fire, KM Roskin, ...
Nature 496 (7446), 469-476, 2013
Broad diversity of neutralizing antibodies isolated from memory B cells in HIV-infected individuals
JF Scheid, H Mouquet, N Feldhahn, MS Seaman, K Velinzon, J Pietzsch, ...
Nature 458 (7238), 636-640, 2009
Structure of HIV-1 gp120 V1/V2 domain with broadly neutralizing antibody PG9
JS McLellan, M Pancera, C Carrico, J Gorman, JP Julien, R Khayat, ...
Nature 480 (7377), 336-343, 2011
Protection of macaques against pathogenic simian/human immunodeficiency virus 89.6 PD by passive transfer of neutralizing antibodies
JR Mascola, MG Lewis, G Stiegler, D Harris, TC VanCott, D Hayes, ...
Journal of virology 73 (5), 4009-4018, 1999
Broad and potent neutralization of HIV-1 by a gp41-specific human antibody
J Huang, G Ofek, L Laub, MK Louder, NA Doria-Rose, NS Longo, ...
Nature 491 (7424), 406-412, 2012
Focused evolution of HIV-1 neutralizing antibodies revealed by structures and deep sequencing
X Wu, T Zhou, J Zhu, B Zhang, I Georgiev, C Wang, X Chen, NS Longo, ...
Science 333 (6049), 1593-1602, 2011
Human skin Langerhans cells are targets of dengue virus infection
SJL Wu, G Grouard-Vogel, W Sun, JR Mascola, E Brachtel, R Putvatana, ...
Nature medicine 6 (7), 816-820, 2000
Structure and immune recognition of trimeric pre-fusion HIV-1 Env
M Pancera, T Zhou, A Druz, IS Georgiev, C Soto, J Gorman, J Huang, ...
Nature 514 (7523), 455-461, 2014
Durability of responses after SARS-CoV-2 mRNA-1273 vaccination
AT Widge, NG Rouphael, LA Jackson, EJ Anderson, PC Roberts, ...
New England Journal of Medicine 384 (1), 80-82, 2021
Developmental pathway for potent V1V2-directed HIV-neutralizing antibodies
NA Doria-Rose, CA Schramm, J Gorman, PL Moore, JN Bhiman, ...
Nature 509 (7498), 55-62, 2014
Tiered categorization of a diverse panel of HIV-1 Env pseudoviruses for assessment of neutralizing antibodies
MS Seaman, H Janes, N Hawkins, LE Grandpre, C Devoy, A Giri, ...
Journal of virology 84 (3), 1439-1452, 2010
The system can't perform the operation now. Try again later.
Articles 1–20